PTC completes acquisition of ST-920 Fabry disease gene therapy
PTCT - PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
PTC Therapeutics completes acquisition of Sangamo’s ST-920 Fabry gene therapy asset
PTC Therapeutics completed its acquisition of Sangamo’s ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease. A rolling BLA filing to the FDA for accelerated approval is expected to be completed in Q4 2026. ST-920, also known as isaralgagene civaparvovec, targets long-term alpha-Gal A enzyme production to re